Royalty Pharma (Royalty Pharma) Tax Rate %

: 0.00% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Royalty Pharma's Tax Expense for the three months ended in Dec. 2023 was $0 Mil. Royalty Pharma's Pre-Tax Income for the three months ended in Dec. 2023 was $718 Mil. Therefore, Royalty Pharma's Tax Rate % for the quarter that ended in Dec. 2023 was 0.00%.

Royalty Pharma Tax Rate % Historical Data

The historical data trend for Royalty Pharma's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Rate %

Royalty Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Tax Rate %																-	-	-	-	-

Royalty Pharma Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Royalty Pharma's Tax Rate % for the fiscal year that ended in Dec. 2023 is calculated as

Tax Rate %	=	Tax Expense (A: Dec. 2023 )	/	Pre-Tax Income (A: Dec. 2023 )
	=	0	/	1700.088
	=	0.00 %

Royalty Pharma's Tax Rate % for the quarter that ended in Dec. 2023 is calculated as

Tax Rate %	=	Tax Expense (Q: Dec. 2023 )	/	Pre-Tax Income (Q: Dec. 2023 )
	=	0	/	717.586
	=	0.00 %

Royalty Pharma Tax Rate % Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

Royalty Pharma (Royalty Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (NAS:RPRX) » Definitions » Tax Rate %

Comparable Companies

Traded in Other Exchanges

RPRX:Mexico RPD:Germany RPD:Germany

Address

110 East 59th Street, FL 33, New York, NY, USA, 10022

Website

https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Executives

Rory B Riggs	director	65 RAILROAD AVE, RIDGEFIELD NJ 07657
Avara Management Ltd	10 percent owner	C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900
Terrance P. Coyne	officer: EVP & CFO	C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Pablo G. Legorreta	director, officer: CEO, Chairman of the Board	110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022
George W. Lloyd	officer: EVP, Investments & GC	C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Marshall Urist	officer: EVP, Research & Investments	C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Mario Germano Giuliani	director, 10 percent owner	C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900
James F. Reddoch	officer: EVP, Research & Investments	C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Nogra Group Sicaf Sif Gg Strategic	10 percent owner	C/O NOGRA GROUP SICAF-SIF S.A., 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227
Nogra Group Sicaf - Sif S.a.	10 percent owner	18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227
Catherine M. Engelbert	director	110 NORTH CARPENTER STREET, CHICAGO IL 60607
Errol B Desouza	director	215 COLLEGE ROAD, PARAMUS NJ 07652
Henry A Fernandez	director	MSCI INC., 88 PINE STREET, NEW YORK NY 10005
Gregory Norden	director	16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005
Ted W Love	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080